A 53-Year-Old Male with Relapsed Diffuse Large B-Cell Lymphoma on Chemotherapy with a New Leg Lesion

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation            | Shi, Connie R., Sarah N. Robinson, Avery LaChance, Martin C. Mihm Jr., and Daniela Kroshinsky. 2017. “A 53-Year-Old Male with Relapsed Diffuse Large B-Cell Lymphoma on Chemotherapy with a New Leg Lesion.” Dermatopathology 4 (1-4): 31-35. doi:10.1159/000481307. http://dx.doi.org/10.1159/000481307. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Published Version   | doi:10.1159/000481307                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Citable link        | http://nrs.harvard.edu/urn-3:HUL.InstRepos:35014946                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Terms of Use        | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
A 53-Year-Old Male with Relapsed Diffuse Large B-Cell Lymphoma on Chemotherapy with a New Leg Lesion

Connie R. Shi a  Sarah N. Robinson b  Avery LaChance b  Martin C. Mihm Jr. c  Daniela Kroshinsky d

a Harvard Medical School, b Harvard Combined Dermatology Residency Program, Departments of c Pathology and d Dermatology, Massachusetts General Hospital, Boston, MA, USA

Keywords
Phaeohyphomycosis · Alternaria

Abstract
Patients with underlying malignancy who develop new skin findings while acutely ill often require skin biopsy for histologic evaluation and/or culture to reach a diagnosis. Here, we present the case of a 53-year-old male with relapsed diffuse large B-cell lymphoma on chemotherapy who developed new skin lesions on the leg. On exam, there were 2 nickel-sized, erythematous to violaceous round plaques with central necrotic cores on the right lower leg with relatively nonspecific clinical features for which the initial differential diagnosis was broad. Consensus on a diagnosis was reached upon histologic evaluation of his skin biopsy in the context of his clinical setting. This diagnosis led to a change in treatment plan, with subsequent clinical improvement.

Case Report
A 53-year-old male with a history of relapsed diffuse large B-cell lymphoma presented with respiratory failure, altered mental status, and distributive shock 4 days status post cycle 1 of rituximab, ifosfamide, carboplatin, and etoposide (RICE) chemotherapy. History was notable for rhinorrhea and cough prior to presentation. Chest CT scan was notable for numerous nodular bilateral opacities concerning for pneumonia. Initial microbiology studies
were notable for a positive bronchoalveolar lavage for *Moraxella catarrhalis*, an elevated (1,3)-β-D-glucan of 184 pg/mL (reference range <60 pg/mL), and negative blood cultures for bacteria or fungi. The patient was treated empirically with vancomycin, cefepime, and azithromycin with little improvement. He remained intubated, requiring pressor support, intravenous fluids, and albumin despite these interventions. Four days after admission, the patient was noted to have developed new cutaneous lesions on the right lower leg. On examination, there were 2 round, red, firm nickel-sized plaques with a central violaceous, necrotic core and collarette of scale on the right lateral lower leg and right medial ankle (Fig. 1). Additionally, there was one red-grey macule on the left shin.

**Diagnosis and Clinical Course**

Histopathologic examination revealed invasive fungal infection with focal angioinvasion and thrombotic vasculopathy (Fig. 2). Grocott-Gomori methenamine silver nitrate, Fontana, and periodic acid-Schiff/diastase stains showed pigmented fungal hyphae within dermal tissue and focally within small vessels (Fig. 2). Fite, acid-fast bacilli, and Gram stains were negative, and *Aspergillus* immunostain was negative. Tissue culture was positive for *Alternaria* species. The histopathologic findings, in conjunction with the patient’s immunosuppression, clinical history, and elevated fungal markers, were suggestive of disseminated *Alternaria* infection. Intravenous liposomal amphotericin B was initiated at 375 mg daily for 10 days. The patient was then transitioned to isavuconazole 372 mg daily and discharged with a plan for a 6-week course of treatment. Four weeks later, following return of final sensitivity data showing a favorable minimal inhibitory concentration of posaconazole, the patient was transitioned to lifetime posaconazole therapy.

**Discussion**

The term phaeohyphomycosis describes a fungal infection caused by a dematiaceous (brown-pigmented) fungus. Among the causative agents of phaeohyphomycosis is *Alternaria*, a genus encompassing nearly 300 species widely found in soil and air, as well as on plant surfaces and human skin [1]. Rarely pathogenic in immunocompetent hosts, an *Alternaria* infection in an immunosuppressed individual can cause cutaneous and subcutaneous infections, oculomycosis, onychomycosis, and sinusitis and, in severe cases, disseminated disease.
involving multiple organ systems [1, 2]. Cutaneous infection typically occurs via direct inoculation through traumatic breaks in the skin [3]. Clinically, cutaneous lesions appear as solitary or multiple nodules and plaques, often with a verrucous or ulcerated appearance [3]. Histopathologic features associated with cutaneous phaeohyphomycosis include epidermal hyperplasia, inflammatory granulomas, and occasionally intraepidermal abscesses and ulceration [3–5]. Fungal hyphae forms may be visualized in the dermal tissue [4, 5].

Immunosuppressed patients are susceptible to localized and disseminated infections with phaeohyphomycoses from dematiaceous fungi, a collection of fungi that characteristically incorporate melanin in the cell wall. Due to the presence of melanin, the dematiaceous fungi appear histologically as brown-black-pigmented hyphae in culture and in tissue [6, 7]. Melanin is thought to be a key virulence factor allowing dematiaceous fungi to escape host defenses by scavenging free radicals and inhibiting phagocytosis [8].

The most common dematiaceous fungi implicated in phaeohyphomycosis are the *Alternaria* species [7]. While a majority of *Alternaria* cases have been reported in transplant recipients [2], individuals with Cushing disease [9], hematologic malignancy [10], and those who are immunosuppressed due to chemotherapy or corticosteroid treatment are also susceptible [3]. Rarely, cases of immunocompetent hosts presenting with alternariosis have been reported [11]. Phaeohyphomycoses are most commonly localized infections of the cutaneous and adjacent subcutaneous tissue. Clinically, these lesions appear as painless nodules and plaques, often with central ulceration [1]. The most common distribution for such cutaneous
lesions is on the extremities [7]. In severe cases, however, phaeohyphomycosis can become disseminated and present with systemic symptoms, such as fevers, as well as involvement of pulmonary, gastrointestinal, and/or central nervous systems [12].

Diagnosis of phaeohyphomycosis depends upon histologic and microbiologic confirmation. At present, there are no available serologic tests that reliably distinguish the dematiaceous fungi [6]. Antigen-based tests, such as (1,3)-β-D-glucan and galactomannan, are not consistently positive for causative agents of phaeohyphomycosis [13]. Early histologic changes associated with cutaneous phaeohyphomycosis include epidermal hyperplasia, inflammatory infiltrates, and microabscesses [4], followed by evolution of inflammatory, suppurative, and purulent granulomas [5]. With regard to special stains, the melanin-specific Masson-Fontana stain is highly sensitive, but not specific, for the identification of dematiaceous fungi in tissue [14]. Caution should be used when interpreting the Masson-Fontana stain due to cross-reactivity with nondematiaceous species, such as Aspergillus and some zygomycetes [14]. Additionally, fungal hyphae of dematiaceous species consistently stain positive with Grocott-Gomori methenamine silver nitrate and periodic acid-Schiff [5]. Fungal culture is needed to definitively identify the causative organism. Furthermore, Alternaria and other dematiaceous molds are common laboratory contaminants [15]; thus, it is critical that a positive fungal culture be not dismissed as a contaminant in cases with consistent clinical and histologic picture.

In our patient, systemic symptoms, lack of initial improvement on broad-spectrum antibacterial coverage, histopathologic findings revealing angioinvasion, as well as global improvement once on antifungal therapy were all suggestive of disseminated phaeohyphomycosis. Elevated (1,3)-β-D-glucan further supported a diagnosis of disseminated, rather than localized, phaeohyphomycosis, though it should be noted that there are reports of false-positive (1,3)-β-D-glucan in the setting of albumin and human blood product administration [16, 17].

Phaeohyphomycosis among individuals who are immunosuppressed is associated with significant mortality, especially if diagnosis is delayed or overlooked. Overall mortality of phaeohyphomycosis among transplant recipients at 1 institution over 20 years was reported at 19% [5], and mortality of disseminated phaeohyphomycosis has been reported as high as 79% [12]. Isolated cutaneous lesions may be surgically excised in addition to treatment with either an oral or intravenous antifungal [12]. The azoles (itraconazole, voriconazole, posaconazole, and the relatively newer agent isavuconazole) are generally effective options for phaeohyphomycosis, and combination therapy including amphotericin B with an azole may be considered for disseminated disease [12, 18]. Choice of therapy should be guided by antifungal susceptibility testing when available. This case highlights the intricacies of diagnosis and treatment of phaeohyphomycosis, specifically Alternaria, in an immunocompromised host. When working up a new lesion in an immunocompromised patient, one must have low threshold for biopsy to assess for infection and consider species that are not typically pathogenic, including Alternaria.

**Statement of Ethics**

The manuscript was prepared in compliance with all ethical and confidentiality guidelines and principles.
Disclosure Statement

The authors have no conflicts of interest to disclose.

References

1. Pastor FJ, Guarro J: Alternaria infections: laboratory diagnosis and relevant clinical features. Clin Microbiol Infect 2008;14:734–746.
2. McCarty TP, Baddley JW, Walsh TJ, Alexander BD, Kontoyiannis DP, Perl TM, et al: Phaeohyphomycosis in transplant recipients: results from the Transplant Associated Infection Surveillance Network (TRANSNET). Med Mycol 2015;53:440–446.
3. Fernandez-Flores A, Saeb-Lima M, Arenas-Guzman R: Morphological findings of deep cutaneous fungal infections. Am J Dermatopathol 2014;36:531–556.
4. Gilaberte M, Bartralot R, Torres JM, Reus FS, Rodriguez V, Alomar A, et al: Cutaneous alternariosis in transplant recipients: clinicopathologic review of 9 cases. J Am Acad Dermatol 2005;52:653–659.
5. Schieffelin JS, Garcia-Diaz JB, Loss GE, Beckman EN, Keller RA, Staffeld-Coit C, et al: Phaeohyphomycosis fungal infections in solid organ transplant recipients: clinical presentation, pathology, and treatment. Transpl Infect Dis 2014;16:270–278.
6. Wong EH, Revankar SG: Dematiaceous molds. Infect Dis Clin North Am 2016;30:165–178.
7. Cockerell C, Mihm Jr MC, Hall BJ, Chisholm C, Jessup C, Merola MC: Dermatopathology: Clinicopathological Correlations, ed 1. London, Springer Science and Business Media, 2013.
8. Nosanchuk JD, Stark RE, Casadevall A: Fungal melanin: what do we know about structure? Front Microbiol 2015;6:1463.
9. Hague J, Liotta E: Subcutaneous phaeohyphomycosis caused by Exophiala jeanselmei in an immunocompromised host. Cutis 2003;72:132–134.
10. Bohelay G, Robert S, Bouges-Michel C, Gerin M, Levy A, Fain O, et al: Subcutaneous phaeohyphomycosis caused by Exophiala spinifera in a European patient with lymphoma: a rare occurrence case report and literature review. Mycoses 2016;59:691–696.
11. Dessinioti C, Soumalevris A, Papadogeorgaki E, Athanasopoulou V, Christofidou E, Antoniou C, et al: Cutaneous alternariosis in an immunocompetent patient successfully treated with oral fluconazole. Eur J Dermatol 2013;23:545–547.
12. Revankar SG, Patterson JE, Sutton DA, Pullen R, Rinaldi MG: Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis 2002;34:467–476.
13. Cuétara MS, Alhambra A, Moragues MD, González-Elorza E, Pontón J, del Palacio A: Detection of (1→3)-β-D-glucan as an adjunct to diagnosis in a mixed population with uncommon proven invasive fungal diseases or with an unusual clinical presentation. Clin Vaccine Immunol 2009;16:423–426.
14. Kimura M, McGinnis MR: Fontana-Masson-stained tissue from culture-proven mycoses. Arch Pathol Lab Med 1998;122:1107–1111.
15. Revankar SG: Phaeohyphomycosis in transplant patients. J Fungi 2015;2:2.
16. Usami M, Ohata A, Horiuichi T, Nagasawa K, Wakabayashi T, Tanaka S: Positive (1→3)-β-D-glucan in blood components and release of (1→3)-β-D-glucan from depth-type membrane filters for blood processing. Transfusion (Paris) 2002;42:1189–1195.
17. Ogawa M, Hori H, Niiguchi S, Azuma E, Komada Y: False-positive plasma (1→3)-β-D-glucan test following immunoglobulin product replacement in an adult bone marrow recipient. Int J Hematol 2004;80:97–98.
18. Falci DR, Pasqualotto AC: Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist 2013;6:163–174.